Biohit Oyj (HEL:BIOBV)

Market Cap	37.54M -25.1%
Revenue (ttm)	15.70M +9.9%
Net Income	2.70M +5.1%
EPS	0.18 +5.0%
Shares Out	15.20M
PE Ratio	13.89
Forward PE	16.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,412
Average Volume	17,719
Open	2.480
Previous Close	2.470
Day's Range	2.440 - 2.490
52-Week Range	2.351 - 3.780
Beta	0.55
RSI	20.44
Earnings Date	Feb 11, 2026

About Biohit Oyj

Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company’s diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist clinicians and general practitioner; BIOHIT Active B12, a test for measuring the concentration of total vitamin-B12 in the serum; BIOHIT Total 25OH Vit...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1988
• Employees: 46
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: BIOBV

Financial Performance

In 2025, Biohit Oyj's revenue was 15.70 million, an increase of 9.92% compared to the previous year's 14.28 million. Earnings were 2.70 million, an increase of 5.14%.